Table 1.
Descriptive statistics
| Mean | SD | Min | Max | |
|---|---|---|---|---|
| Panel A: labeled plant phenotype (3,511 symptom sessions, 1,118 users) | ||||
| Hybrid | 0.48 | 0.50 | 0 | 1 |
| C. indica | 0.18 | 0.38 | 0 | 1 |
| C. sativa | 0.35 | 0.48 | 0 | 1 |
| Panel B: combustion method (3,667 symptom sessions, 1,147 users) | ||||
| Joint | 0.17 | 0.38 | 0 | 1 |
| Pipe | 0.49 | 0.50 | 0 | 1 |
| Vape | 0.34 | 0.47 | 0 | 1 |
| Panel C: THC (1,469 symptom sessions, 517 users) | ||||
| % THC | 19.09 | 7.33 | 0 | 35 |
| THC <10% | 0.14 | 0.35 | 0 | 1 |
| THC 10–19% | 0.39 | 0.49 | 0 | 1 |
| THC 20–35% | 0.47 | 0.50 | 0 | 1 |
| Panel D: CBD (901 symptom sessions, 369 users) | ||||
| % CBD | 5.95 | 7.65 | 0 | 35 |
| CBD <1% | 0.34 | 0.47 | 0 | 1 |
| CBD 1–9% | 0.37 | 0.48 | 0 | 1 |
| CBD 10–35% | 0.29 | 0.45 | 0 | 1 |
| Panel E: outcome and control variables (3,922 symptom sessions, 1,224 users) | ||||
| Symptom change | –3.48 | 2.70 | –10 | 9 |
| Starting symptom level | 6.08 | 2.10 | 1 | 10 |
| Ending symptom level | 2.60 | 2.24 | 0 | 10 |
| Total dose | 8.49 | 9.65 | 1 | 149 |
| Panel F: side effects (3,247 sessions, 1,020 users) | ||||
| Any negative side effect | 0.68 | 0.47 | 0 | 1 |
| Negative side effects, % | 0.13 | 0.16 | 0 | 1 |
| Any positive side effect | 0.96 | 0.20 | 0 | 1 |
| Positive side effects, % | 0.31 | 0.21 | 0 | 1 |
| Any context-specific side effect | 0.81 | 0.39 | 0 | 1 |
| Context-specific side effects, % | 0.23 | 0.23 | 0 | 1 |
Sample includes sessions with fatigue as the symptom reported. Nineteen positive, seventeen negative, and eleven context-specific side effects were available for selection.